Company / R&D Expense
Nuvation Bio Inc. R&D Expense History
FY2020-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$115.1M
FY2025
5-year range
$69.0M / $115.1M
FY2021-FY2025
Trend
+16.1%
vs FY2024
Sector context
#133 of 210
Health Care
What the data says
At $115M, Nuvation Bio Inc.'s r&d expense ranks #133 of 210 in the Health Care sector. Improved from $71M to $115M over the past 2 years.
Based on SEC 10-K filings.
$115M in FY2025 with a 5-year CAGR of +28.7%.
Improved from $71M to $115M over the past 2 years.
Health Care sector context is included.
R&D Expense over time
Growth rates
- 3-Year CAGR
- +9.4%
- 5-Year CAGR
- +28.7%
- 10-Year CAGR
- -
Sector benchmark
#133 of 210 in Health CareTop 63% of 210This company $115.1M Sector average $644.1M
▼
-82.1% below sector average
Key checks
Key Insights
- 5-year CAGR of +28.7%, indicating consistent growth.
- In FY2025, r&d expense increased 16.1% year-over-year.
- Ranks #133 out of 210 companies in the Health Care sector.
- Lowest r&d expense in the period was in FY2020.
Company context
Key Data Points
- Altman Z-Score -1.56 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $115.1M | +16.1% |
| FY2024 | $99.1M | +39.0% |
| FY2023 | $71.3M | -18.8% |
| FY2022 | $87.8M | +27.2% |
| FY2021 | $69.0M | +111.8% |
| FY2020 | $32.6M | - |
As of FY2025 · SEC 10-K · Updated Mar 29, 2026